Author

Ruchi Upmanyu

Observed names: R Upmanyu, R. Upmanyu, Upmanyu, R., Upmanyu, Ruchi

Observed institutions: National Health Service, deCODE Genetics (Iceland), Mayo Clinic, Shanghai Jiao Tong University, King's College London, Virginia Commonwealth University, GlaxoSmithKline (United Kingdom), Fudan University, Montreal Heart Institute, Ruijin Hospital, Denver VA Medical Center, Nanfang Hospital, Roche (United Kingdom), First Hospital of Jilin University, GlaxoSmithKline Research & Development Limited (United Kingdom), Southern Medical University, Université de Montréal, Medical Research Council, University of Colorado Denver

OpenAlex ID: A5007814849

Candidate Single-Nucleotide Polymorphisms From a Genomewide Association Study of Alzheimer Disease

2007 · Hao Li, Sally Wetten, et al. · Archives of Neurology · 499

Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry

2009 · Laura J. Scott, Pierandrea Muglia, et al. · Proceedings of the National Academy of Sciences · 314

Genome-wide association study of recurrent major depressive disorder in two European case–control cohorts

2008 · P Muglia, F Tozzi, et al. · Molecular Psychiatry · 265

PDF

LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study

2008 · Mary M Hulihan, Lianna Ishihara-Paul, et al. · The Lancet Neurology · 191

Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib

2015 · Jean-Claude Tardif, Eric Rhéaume, et al. · Circulation Cardiovascular Genetics · 183

A Susceptibility Gene for Psoriatic Arthritis Maps to Chromosome 16q: Evidence for Imprinting

2003 · Ari Karason, Johann E. Gudjonsson, et al. · The American Journal of Human Genetics · 180

PDF

Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes

2003 · J.E. Gudjonsson, A. Karason, et al. · British Journal of Dermatology · 118

Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)

2014 · Clifton O Bingham, Warren Rizzo, et al. · Annals of the Rheumatic Diseases · 108

PDF

Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B

2024 · Jinlin Hou, Wenhong Zhang, et al. · New England Journal of Medicine · 88

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

2014 · Kausik K. Ray, Marc Ditmarsch, et al. · European Heart Journal · 87

A Genome-Wide Significant Linkage for Severe Depression on Chromosome 3: The Depression Network Study

2011 · Gerome Breen, Bradley Todd Webb, et al. · American Journal of Psychiatry · 69

PINK1 mutations and parkinsonism

2008 · L. Ishihara-Paul, M. M. Hulihan, et al. · Neurology · 64

PDF

IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis

2013 · Jianmei Wang, Adam Platt, et al. · BMJ Open · 60

PDF

Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis

2012 · J Wang, A T Bansal, et al. · The Pharmacogenomics Journal · 50

PDF

TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial

2022 · Man-Fung Yuen, Rozalina Balabanska, et al. · The Lancet Infectious Diseases · 44

OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)

2024 · Jinlin Hou, Qing Xie, et al. · Journal of Hepatology · 9

RO7020531, a novel prodrug of a toll-like receptor 7 agonist, is safe, well tolerated and activates TLR signaling in healthy volunteers

2018 · E. Gane, I. Folitar, et al. · Journal of Hepatology · 5

THU0503 Identification of optimal subcutaneous (SC) doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis (PCJIA)

2017 · F De Benedetti, N Ruperto, et al. · Annals of the Rheumatic Diseases · 3

PDF

Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod

2024 · Qiudi Jiang, Yuchen Zhang, et al. · Clinical and Translational Science · 2

PDF

TLR7 agonist ro7020531 triggers immune activation after multiple doses in chronic hepatitis B patients

2018 · E. Gane, K Agarwai, et al. · 1

06. Identification of optimal subcutaneous doses of tocilizumab in children with polyarticular-course juvenile idiopathic arthritis

2017 · Shazad Jafri, Athimalaipet V. Ramanan, et al. · Lara D. Veeken · 1

Outcomes of nucleos(t)ide analogue discontinuation following finite xalnesiran-based therapies in chronic hepatitis B

2026 · Cong Cheng, Qing Xie, et al. · JHEP Reports

THU-270 HBV genotype association with response to xalnesiran in nucleos (t)ide analogue treated participants with chronic hepatitis B infection in the Piranga phase 2 platform study

2025 · Emma Bell, Annabelle Lemenuel-Diot, et al. · Journal of Hepatology

Abstract 16388: Efficacy and Safety of Early Dalcetrapib Treatment on Lipid Profile and Markers of HDL Functionality in Patients Hospitalized for an Acute Coronary Syndrome - The dal-ACUTE Study

2012 · Kausik K. Ray, Marc Ditmarsch, et al. · Circulation

FRI0106 Preliminary results from a controlled trial (VISARA) to evaluate the humoural immune response to vaccines in RA patients treated with tocilizumab (TCZ)

2012 · C.O. Bingham, W. Rizzo, et al. · Annals of the Rheumatic Diseases

Works count: 31

Citation count: 2,342

H-index: 15

I10-index: 15